Research
Hormonal
Ketogenic diets improve glycemic control in Type 2 Diabetes patients by reducing carbohydrate intake, thereby lowering insulin levels and HbA1c, and reducing the need for insulin medication.
If you have Type 2 Diabetes, restricting carbs to under 30g/day can significantly lower your HbA1c and reduce your need for insulin. Work with your doctor to adjust medications as your blood sugar improves.
GoodSupportsHIGH confidence
KD has helped patients with diabetes reduce their HbA1c and reduce the need for insulin... The reduction of carbohydrate intake naturally reduces blood glucose levels, thus reducing insulin as a result. Many studies have now demonstrated that the ketogenic diet reduces both blood glucose and insulin levels
Why this rating
Cites multiple studies showing reduced HbA1c and insulin needs.
Source
The Potential Health Benefits of the Ketogenic Diet: A Narrative Review
Kathryn Dowis et al. · Nutrients · 2021
DOI 10.3390/nu13051654
narrative_reviewCited 236×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- A ketogenic diet (carbohydrate restriction <50g/day) promotes weight loss and visceral adiposity reduction by inducing nutritional ketosis, which suppresses appetite via beta-hydroxybutyrate (BHB) signaling and increases energy expenditure through fat oxidation.Good
- Ketogenic diets positively affect the gut microbiome by increasing the ratio of Bacteroidetes to Firmicutes and increasing beneficial bacteria like Bifidobacteria and butyrate-producing species.Moderate
- Ketogenic diets may have anti-cancer effects by exploiting the Warburg effect, starving cancer cells of glucose and making them more vulnerable to chemotherapy and radiation.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →